Statistical analysis
tumor, death
DISEASE PROGRESSION, TUMOR
The safety analysis set consisted of patients who received at least 1 dose of fruquintinib and was used in safety and PFS analyses. The efficacy analysis set included patients who received at least 1 dose of fruquintinib, had measurable target lesions at baseline, and had either at least 1 tumor assessment after treatment, or no tumor assessment after treatment but clinical progression as noted by the Investigator, or death due to disease progression before their first tumor scan after treatment. ORR and DCR were calculated with 2-sided 95% confidence intervals (CIs) using the Clopper-Pearson method [